Jencap Research Ltd.

Ares Trading S.a.

Circadian Zirclight Inc.

Other

Wayne State University

Korrus, Inc.

Mount Sinai Hospital Corporation

Duramed Pharmaceuticals, Inc.

Melcort Inc.

1333366 Ontario Inc.

Duramed Pharmaceutials, Inc.

Casper, Robert

Wardrop, Jennifer

Spilkin, Jonathan

Solo, Peter

Robert Frederic Casper

Mohamed F M Mitwally

Martin Christopher Moore-Ede

Anneke Marlies Heitmann

Doros Platika

Udo Trutschel

Rebecca Mary Chacko

Robert Frank Karlicek, Jr

Gary A Shangold

Militza K Ausmanas

Michael P Diamond

Ian Rogers

Howard Charles Tenenbaum

Peter Solo

Jonathan Spilkin

Jennifer Wardrop

Shadab Rahman

Zeev Shoham

Gideon Kopernik

Shadab A Rahman

Jr Karlicek Robert Frank

Wardrop Jennifer

Spilkin Jonathon

Solo Peter

Rahman Shadab

Lighting systems, methods, and devices for protecting human circadian neuroendocrine function during night use are described. Suitable lighting conditions can be provided for a working environment while protecting the circadian neuroendocrine systems of those occupying the illuminated workplace during the night. Lighting systems, methods, and devices can provide substantive attenuation of the pathologic circadian disruption in night workers. Lighting systems, methods, and devices can attenuate the specific bands of light implicated in circadian disruption. LED lighting systems, methods, and devices can provide increased intensity at a different portion of the spectrum than conventional LEDs, providing a useable white light even when unfavorable portions of the wavelength are attenuated by a notch filter. LED lighting systems, methods, and devices can switch between a daytime configuration and a night time configuration, wherein the daytime configuration provides unfiltered light and the night time configuration provides filtered light.

Lighting system for protecting circadian neuroendocrine function

A method and device for improving sleep performance of a subject exposed to an artificially lighted environment at night are provided, which involve selectively substantially blocking retinal exposure of the subject to light of specified wavelengths during the night.

Methods and devices for improving sleep performance in subject exposed to light at night

The present invention provides an improved method to deliver estrogen to menopausal women comprising administering ultra-low dose estradiol alternating with standard-dose estradiol.

Estrogen replacement regimen

Aromatase inhibitors are administered to a female patient prior to endometrial ablation or resection procedures in order to thin the endometrium to a thickness of less than 6 mm, and preferably less than 4 mm, so as to enhance the treatment outcome. Of course, administration of aromatase inhibitors would be useful for other surgical procedures on the endometrial cavity and the uterus. Commercially available aromatase inhibitors, including, the nonsteroidal preparations, anastrozole and letrozole, and a steroidal agent, exemestane, are well-tolerated, and have been shown to decrease serum estrogen levels. The aromatase inhibitor can be used alone, or in combination with other aromatase inhibitors or pharmaceutical agents, such as hormones.

Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus

Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In certain preferred embodiments, the aromatase inhibitor is administered in conjunction with methotrexate.

Use of aromatase inhibitors for treatment of ectopic pregnancy

The use of an aromatase inhibitor (AI) in the preparation of a medicament for use in inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female a single dose of the at least one aromatase inhibitor. The use of an aromatase inhibitor (AI) for the preparation of a medicament comprising a single dose of at least one aromatase inhibitor (AI) for administration to an ovulating female suffering from unexplained infertility or other types of ovulatory infertility early in one or more menstrual cycles. Such a medicament may also be administered to an anovulatory female in combination with a plurality of daily doses of follicle stimulating hormone (FSH) whereby the dosage levels of FSH may be reduced. The use of AI in the preparation of a medicament for administration to a female who is a poor responder to FSH, which comprises a combination of a single dose of AI with a plurality of daily doses of FSH is also disclosed. The related pharmaceutical preparations and packages are also described.

Single dose aromatase inhibitor for treating infertility

The use of at least one aromatase inhibitor in the production of a medicament for improving the implantation and pregnancy rates for a female undergoing assisted reproduction treatment, which comprises one or more daily doses of an aromatase inhibitor (AI) for administration during assisted reproduction cycles or ovarian stimulation cycles, wherein the doses of AI are selected from amounts effective to reduce serum estradiol levels. Also disclosed are related pharmaceutical preparations and packages.

Aromatase inhibition to enhance assisted reproduction

A method of inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor. A method for augmenting ovulation in an ovulating female suffering from unexplained infertility or another type of ovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor early in one or more menstrual cycles. A method of substantially reducing dosage levels of follicle stimulating hormone (FSH) for administration to a female undergoing infertility treatment which comprises administering a combination of two or more daily doses of at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). A method of increasing response to a follicle stimulating hormone from a female who is a poor responder to follicle stimulation, which comprises administering a combination of two or more daily doses or at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). Also disclosed are related pharmaceutical preparations and uses.

Multiple dose aromatase inhibitor for treating infertility

The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hematopoietic stem and progenitor cells.

Cellular compositions and methods of making and using them

The present invention provides a device for inhibiting melatonin suppressing light from reaching the retina. The device having means for selectively blocking light having a wavelength capable of suppressing melatonin production in a human.

Device for the prevention of melationin suppression by light at night

A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&#x3b2;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&#x3b2;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &#x3bc;g per day of norgestimate.

Low dose estrogen interrupted hormone replacement therapy

Growing community of inventors

Toronto, Canada

Robert Frederic Casper